CAS Medical Systems Inc.

CAS Medical Systems Inc.

CAS Medical Systems Inc.

Date Founded



44 East Industrial Road, Branford, CT, 06405, USA

Type of Company


Employees (Worldwide)



Medical Products & Equipment
Hospitals & Patient Services
Industrial Machinery & Manufacturing

Company Description

CAS Medical Systems, Inc. develops, manufactures, and markets non-invasive patient monitoring products that are vital to patient care. Its products include the FORE-SIGHT Absolute Tissue Oximeter and sensors, and its traditional monitoring products which include MAXNIBP blood pressure measurement technology. CAS Medical Systems was founded in 1984 and is headquartered in Branford, CT.

Contact Data
Trying to get in touch with decision makers at CAS Medical Systems Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Scientific Officer

Executive Vice President of US Sales

Vice President of Global Marketing


Chief Financial Officer & Vice President


Director of Billing

Operations Director

Tradeshow Coordinator

Board of Directors

Former President at Novametrix Medical Systems, Inc.

President & Chief Executive Officer at Clearflow, Inc.

Principal Accounting Officer at Edwards Lifesciences Corp.

Paths to CAS Medical Systems Inc.
Potential Connections via
Relationship Science
CAS Medical Systems Inc.
Recent Transactions
Details Hidden

Edwards Lifesciences Corp. purchases CAS Medical Systems Inc.

Details Hidden

Halma Plc, SunTech Medical, Inc. purchase Cas Medical Systems, Inc. /NIBP Business from CAS Medical Systems Inc.

Details Hidden

Trinity Medical Devices, Inc. purchases CAS Medical Systems, Inc. /Neonatal Business from CAS Medical Systems Inc.

Transaction Advisors

Advised onCAS Medical Systems Inc. issued Common Stock

Legal Advisor

Advised onEdwards Lifesciences Corp. purchases CAS Medical Systems Inc.


Advised onCAS Medical Systems Inc. issued Common Stock

Chair, Corporate Department

Advised onEdwards Lifesciences Corp. purchases CAS Medical Systems Inc.

Advisors & Consultants

Managing Director at Lippert/Heilshorn & Associates, Inc.


Senior Vice President & Principal at Lippert/Heilshorn & Associates, Inc.


Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

The University of Chicago's Office of Investments (COI) is responsible for managing the University's investment assets, which includes overseeing the endowment to ensure that it benefits both current and future generations of the University of Chicago. COI oversees the broad investment strategy and provides input to the development of the strategic and tactical investment policies of the University & UCMC endowments, pension plans and self-insurance trust assets. Their strategy combines qualitative and quantitative analysis, seeking to achieve superior investment performance on a risk-adjusted basis.COI's approach seeks to evaluate the investment strategy as an integrated part of the operating plans of the University rather than in isolation and focuses the the University's overall success, not investment returns. The endowment is well-diversified across a variety of asset classes, including global stocks and bonds, real estate, natural resources, private equity, absolute return strategies and protection (tail-hedging strategies). Asset class exposure is achieved primarily by selecting and engaging external managers. COI manages the global macro and the overlay portfolio to ensure that the portfolio's overall positioning is compliance with the endowment's investment guidelines.COI's strategies for investing in the public markets include: Absolute Return, Private Debt, Fixed Income and Credit. and Global Equities.COI's real assets team invests globally in real estate and natural resources using outside managers. The real estate portfolio invests globally in value-added and opportunistic strategies using both private partnerships and public vehicles. The natural resources portfolio invests globally in strategies that include, but are not limited to: oil and gas exploration & production; power generation; infrastructure; timber; mining and minerals; and agriculture.

The NewYork-Presbyterian Healthcare System NewYork-Presbyterian Healthcare System Leadership The NewYork-Presbyterian Healthcare System is a federation of top-quality hospitals, specialty institutes, and continuing care centers throughout New York, New Jersey, and Connecticut. It was founded to bring about a positive change in the way healthcare is delivered to the community. Most System members are academic affiliates of either Weill Cornell Medical College or Columbia University College of Physicians and Surgeons. Weill Cornell Medical College Columbia University College of Physicians and Surgeons The NewYork-Presbyterian Healthcare System is dedicated to improving patient care, medical education and research throughout this region of the United States. Member Healthcare Institutions The requirements of modern medicine are more challenging than ever. What we've learned in the last century will pale in comparison to what we'll accomplish in the next. And, as medicine evolves, so does the need to share this knowledge and harness what we discover- because the list of devastating, heartbreaking diseases awaiting a cure remains long. That's why all of us within the NewYork-Presbyterian Healthcare System are constantly looking for ways to improve every aspect of patient care. We draw upon the research capacity and academic infrastructure of two Ivy League medical schools, Columbia University College of Physicians and Surgeons and Weill Cornell Medical College, to improve the knowledge base within our member institutions, with the goal of providing every patient the best possible treatment.

Key Stats and Financials As of 2018
Market Capitalization
Total Enterprise Value
Earnings Per Share
Details Hidden

TMT invests in life science and medical technology companies at all stages of development. The firm targets investments in pharmaceutical, medical device, biotechnology and diagnostic sectors and in other areas utilizing medical technology innovation. TMT participates in restructuring transactions including spin-outs, roll ups and recapitalizations.TMP typically invests $5 million to $40 million in one or more rounds of financing, with an average investment of more than $15 million over the life of an investment. Initial investments may be as small as $100,000. The firm prefers to lead the financing round in which they first participate.

Medtronic Plc Medical Products & Equipment - Dublin, DU

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular divisions. The Minimally Invasive Technologies Group segment comprises Surgical Innovations and Respiratory, Gastrointestinal, and Renal divisions. The Restorative Therapies Group contains Spine, Brain, Specialty Therapies, and Pain Therapies divisions. The Diabetes Group segment focuses in the development, manufacturing, and marketing of products and services for the management of Type I and Type II diabetes. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Masimo Corporation Medical Products & Equipment - IRVINE, CA

Masimo (NASDAQ: MASI) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors. A key medical technology innovator, Masimo is responsible for the invention of award-winning noninvasive technologies that are revolutionizing patient monitoring, including Masimo SET® pulse oximetry, Masimo rainbow® SET Pulse CO-Oximetry and new Masimo noninvasive and continuous total hemoglobin (SpHb®) monitoring technology. These new rainbow® technologies are expected to open new markets and significantly expand the company’s growth opportunities. Joe Kiani founded Masimo in 1989 as a private "garage start-up" company because he was convinced that the use of adaptive signal processing in the measurement of physiological parameters could solve the problems of low perfusion and motion, which had long plagued in-vivo monitoring and especially pulse oximetry. Today, Masimo has grown into a successful publicly traded medical technology company employing over 2,500 people worldwide with product revenues that have increased 4-fold in the last five years. In addition, the company has technology license and OEM agreements with leading patient monitoring manufacturers spanning the globe including Atom, Datascope, GE Medical, Medtronic, Philips, Spacelabs, and Zoll. Masimo is not only the inventor of Measure-through Motion and Low Perfusion pulse oximetry and Pulse CO-Oximetry technologies, but is also the market-leading pulse oximetry technology solution. In 1995, Masimo debuted Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo SET—a breakthrough in pulse oximetry technology that virtually eliminated false alarms and increased pulse oximetry’s ability to detect life-threatening events. More than 100 independent and objective studies demonstrate that Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow® SET Pulse CO-Oximetry, a breakthrough noninvasive blood constituent monitoring platform that measures many blood constituents that previously required invasive procedures. Masimo rainbow SET continuously and noninvasively measures total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®) and pleth variability index (PVI®), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), enabling early detection and treatment of potentially life-threatening conditions. For more than 20 years now, Masimo has been focused on a singular mission—to create noninvasive patient monitoring technologies that are more effective and reliable and to improve patient outcomes and reduce the cost of care by bringing these technologies to new sites and applications. The result is a portfolio of clinically-proven products that lead the way in innovation, performance and patient safety by giving health care providers the information they need to optimize clinical decision-making

Hamamatsu Photonics KK Electrical Products - Hamamatsu, SZ

Hamamatsu Photonics KK engages in the manufacture and sale of imaging and analyzing systems, photomultiplier tubes, imaging devices, light sources, and opto-semiconductors. It operates through the following segments: Electron Tube, Opto-semiconductor, Imaging and Measurement Instruments, and Others. The Electron Tube segment produces photomultiplier tubes, light sources, and imaging devices. The Opto-semiconductor segment offers optical semiconductor devices. The Imaging and Measurement Instruments segment deals with image processing and measurement systems. The Others segment includes semiconductor lasers and hotel businesses. The company was founded by Heihachiro Horiuchi in September 1948 and is headquartered in Hamamatsu, Japan.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by CAS Medical Systems Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of CAS Medical Systems Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and CAS Medical Systems Inc..